Browsing Tag
Alexander disease
2 posts
Ionis Pharmaceuticals (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails, Alnylam Amvuttra and BridgeBio Attruby emerge as clear beneficiaries
Ionis (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails primary endpoint. Peak sales cut to $4B. Alnylam and BridgeBio benefit from the reset.
Can zilganersen become the first disease-modifying therapy for Alexander disease?
Ionis wins FDA breakthrough therapy status for zilganersen in Alexander disease. Find out what this means for rare neurology drug development.